Suppr
超能文献

The Future of Radioligand Therapy: α, β, or Both?

作者信息

Haberkorn Uwe, Giesel Frederik, Morgenstern Alfred, Kratochwil Clemens

机构信息

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; and.

出版信息

J Nucl Med. 2017 Jul;58(7):1017-1018. doi: 10.2967/jnumed.117.190124. Epub 2017 Apr 13.

DOI:10.2967/jnumed.117.190124

PMID:28408527

Abstract

摘要

相似文献

The Future of Radioligand Therapy: α, β, or Both?

J Nucl Med. 2017 Jul;58(7):1017-1018. doi: 10.2967/jnumed.117.190124. Epub 2017 Apr 13.

The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):271-3. doi: 10.1007/s00259-010-1707-7.

More α Than β for Prostate Cancer?

J Nucl Med. 2017 Nov;58(11):1709-1710. doi: 10.2967/jnumed.117.198333. Epub 2017 Sep 21.

Ac-225 and her daughters: the many faces of Shiva.

Cell Death Differ. 2002 Jun;9(6):593-4. doi: 10.1038/sj.cdd.4401047.

Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.

Crit Rev Oncol Hematol. 2018 Mar;123:7-20. doi: 10.1016/j.critrevonc.2018.01.001. Epub 2018 Jan 10.

Therapeutic Radiometals Beyond Lu and Y: Production and Application of Promising α-Particle, β-Particle, and Auger Electron Emitters.

J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S. doi: 10.2967/jnumed.116.186825.

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

Cancer Res. 2011 Feb 1;71(3):1009-18. doi: 10.1158/0008-5472.CAN-10-1186. Epub 2011 Jan 18.

A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.

J Nucl Med. 2012 Dec;53(12):1951-9. doi: 10.2967/jnumed.112.107540. Epub 2012 Nov 8.

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.

J Nucl Med. 2018 Jul;59(7):1020-1027. doi: 10.2967/jnumed.117.204651. Epub 2018 Mar 1.

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.

引用本文的文献

Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers.

Mol Pharm. 2025 Jul 7;22(7):4019-4031. doi: 10.1021/acs.molpharmaceut.5c00288. Epub 2025 May 29.

Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.

Cancers (Basel). 2025 Apr 7;17(7):1247. doi: 10.3390/cancers17071247.

Clinical application of targeted α-emitter therapy in gastroenteropancreatic neuroendocrine neoplasms.

J Gastroenterol. 2025 Apr 12. doi: 10.1007/s00535-025-02241-z.

JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.

Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1631-1641. doi: 10.1007/s00259-024-07044-7. Epub 2025 Jan 2.

Effect of molar dose on the in vivo tissue biodistribution profile of FAP-targeted radioligand therapeutics.

Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1399-1405. doi: 10.1007/s00259-024-06969-3. Epub 2024 Nov 12.

Novel astatine (At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.

Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):469-481. doi: 10.1007/s00259-024-06945-x. Epub 2024 Oct 12.

Role of Lutetium Radioligand Therapy in Prostate Cancer.

Cancers (Basel). 2024 Jul 1;16(13):2433. doi: 10.3390/cancers16132433.

Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.

Nat Rev Urol. 2025 Jan;22(1):26-45. doi: 10.1038/s41585-024-00900-z. Epub 2024 Jul 8.

Actinium-225 targeted alpha particle therapy for prostate cancer.

Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. eCollection 2024.

Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.

Curr Oncol. 2024 Mar 7;31(3):1400-1415. doi: 10.3390/curroncol31030106.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

The Future of Radioligand Therapy: α, β, or Both?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译